The International Project Team Lead for the lemborexant clinical development program shares insights from their presentations at the Virtual SLEEP 2020 Meeting.
At the recent Virtual SLEEP 2020 Meeting, Eisai gave 2 presentations. One of these was on lemborexant, which was recently launched in the US for the treatment of adult patients with insomnia, characterized by difficulties with sleep onset and/or sleep maintenance.
In these presentations, data on the following topics were shared:
1. Long-term results evaluating lemborexant efficacy and safety in adults ages 65 and older, in measures of time to sleep onset, sleep efficacy, and sleep maintenance.
2. Efficacy and safety results of lemborexant in female subjects of perimenopausal age from SUNRISE 2.
3. An open-label pilot study evaluating the ability of patients with insomnia disorder to directly transition from zolpidem to lemborexant.
4. The impact of lemborexant on fatigue severity.
Dr Moline is the International Project Team Lead for the lemborexant clinical development program at Eisai.